HMNC Brain Health and Spruce Biosciences have dosed the first patient in the Phase 2 TAMARIND clinical trial. This trial is investigating tildacerfont, a CRF1 receptor antagonist, as a treatment for Major Depressive Disorder (MDD) in patients selected using HMNC’s investigational patient selection tool. The tool aims to identify patients with HPA axis dysregulation, a biologically distinct subtype of MDD, who are more likely to benefit from this targeted therapy.
This trial is necessary because it represents a shift towards precision psychiatry for MDD. Current MDD treatment often involves a trial-and-error approach with various medications. By targeting a specific biological mechanism (HPA axis dysregulation) and selecting patients most likely to respond, the TAMARIND trial has the potential to improve treatment efficacy and reduce the time and cost associated with finding the right therapy. This personalized approach could significantly enhance patient outcomes.
TAMARIND is a randomized, double-blind, placebo-controlled study enrolling 88 adults with MDD selected using HMNC’s patient selection tool. The eight-week treatment period will assess the safety, efficacy, and tolerability of tildacerfont. The primary endpoint is the change in depression scores from baseline, measured using the Hamilton Depression Rating Scale. Secondary endpoints include functional impairment and overall quality of life. Topline results are expected in the first half of 2026.
The TAMARIND trial’s outcome could have a significant impact on the MDD treatment landscape. Positive results could validate HMNC’s patient selection tool and establish tildacerfont as a precision medicine for this subtype of MDD. This could lead to a more personalized and effective approach to MDD treatment, benefiting both patients and the healthcare system. Furthermore, the trial’s success may stimulate additional research and development in precision psychiatry for other mental health disorders.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
